(Q64926521)

English

Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.

scientific article published on 18 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. (English)

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Andréa Teixeira de Carvalho

7

object named as

Andréa Teixeira-Carvalho

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Renato Sathler-Avelar

6

object named as

Renato Sathler-Avelar

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Márcio Sobreira Silva Araújo

1

object named as

Márcio Sobreira Silva Araújo

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

author name string

Renata Aline de Andrade

2

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Leonardo Rocha Vianna

3

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Wilson Mayrink

4

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Alexandre Barbosa Reis

5

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Mariléia Chaves Andrade

8

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Maria Norma Mello

9

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Olindo Assis Martins-Filho

10

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

language of work or name

0 references

publication date

18 March 2008

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

26

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

18

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

2211-2224

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Lutzomyia longipalpis and the eco-epidemiology of American visceral leishmaniasis, with particular reference to Brazil: a review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

The current status of zoonotic leishmaniases and approaches to disease control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Assessment of an optimized dog-culling program in the dynamics of canine Leishmania transmission.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Epidemiology of canine visceral leishmaniosis in the endemic area of Montes Claros Municipality, Minas Gerais State, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

based on heuristic

inferred from DOI database lookup

Visceral leishmaniasis in the hoary zorro Dusicyon vetulus: a case of mistaken identity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Identification of Leishmania chagasi antigens recognized by human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Progress in vaccine research and possible effector mechanisms in visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Studies of canine leucocyte antigens: a significant advance in canine immunology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Expression of adhesion and Fcgamma-receptors on canine blood eosinophils and neutrophils studied by anti-human monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Canine leishmaniasis: epidemiological risk and the experimental model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmaniasis reservoirs and their significance in control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Chemotherapy of canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Treatment of canine Old World visceral leishmaniasis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Toll-like receptor control of the adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Expression and function of Toll-like receptor 2 in canine blood phagocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Triggering TLR signaling in vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Inter-relationship among macrophages, natural killer cells and neutrophils in early stages of Listeria resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Cytokine cross-talk between phagocytic cells and lymphocytes: relevance for differentiation/activation of phagocytic cells and regulation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmanicidal Mechanisms of Human Polymorphonuclear Phagocytes *

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

In vivo involvement of polymorphonuclear neutrophils in Leishmania infantum infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

The cell biology of T-dependent B cell activation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Fc receptors and immunity to parasites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Expression of functional activating and inhibitory Fcgamma receptors on human B cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Tolls for B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

The cross-priming pathway: a portrait of an intricate immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Histopathology, parasite density and cell phenotypes of the popliteal lymph node in canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Adjuvant effects of saponins on animal immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Recent advances in veterinary vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.044

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.02.044

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

1 reference

Europe PubMed Central

1 July 2019

http://europepmc.org/abstract/MED/18395948

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64926521&oldid=1905612767"